We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-24.99%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$160M
AUM Growth
-$78.8M
Cap. Flow
-$21.6M
Cap. Flow %
-13.46%
Top 10 Hldgs %
42.9%
Holding
67
New
14
Increased
18
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.49M
2
CMRX
Chimerix, Inc.
CMRX
+$4.41M
3
TVRD
Tvardi Therapeutics
TVRD
+$3.55M
4
IMMU
Immunomedics Inc
IMMU
+$2.33M
5
SAGE
Sage Therapeutics
SAGE
+$2.29M

Top Sells

Rank Stock Value
1
RLYP
RELYPSA INC COM
RLYP
+$6.24M
2
CEMP
Cempra, Inc.
CEMP
+$6.23M
3
TNXP icon
Tonix Pharmaceuticals
TNXP
+$4.33M
4
AVGR
Avinger, Inc. Common Stock
AVGR
+$4.32M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$3.85M

Sector Composition

Rank Sector Weight
1 Healthcare 88.12%
2 Miscellaneous 11.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFMD
26
DELISTED
Affimed
AFMD
$2.28M 1.42%
61,000
+1,500
+3% +$56.5K
ZGNX
27
DELISTED
Zogenix, Inc.
ZGNX
$2.22M 1.38%
240,000
+90,000
+60% +$902K
TVTX icon
28
Travere Therapeutics
TVTX
$6.36B
$2.05M 1.28%
150,000
-195,000
-57% -$2.96M
SUPN icon
29
Supernus Pharmaceuticals
SUPN
$2.57B
$1.91M 1.19%
125,000
-295,000
-70% -$3.85M
TRIL
30
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.8M 1.13%
195,000
-15,000
-7% -$126K
PDSB icon
31
PDS Biotechnology
PDSB
$12.2M
$1.69M 1.06%
+9,250
New +$1.65M
CYNA
32
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$1.44M 0.9%
121,000
+11,000
+10% +$147K
ADAP
33
DELISTED
Adaptimmune Therapeutics
ADAP
$1.43M 0.89%
+175,300
New +$1.43M
CORI
34
DELISTED
Corium International, Inc.
CORI
$1.39M 0.87%
360,000
+5,000
+1% +$26.3K
CYTO
35
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.24M 0.77%
4
-1
-20% -$356K
NBSE
36
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.18M 0.73%
+915
New +$1.3M
XOMA
37
DELISTED
Xoma
XOMA
$1.04M 0.65%
67,500
-17,500
-21% -$315K
TENX icon
38
Tenax Therapeutics
TENX
$82M
$1.02M 0.64%
16
-1
-6% -$77.7K
AKAO
39
DELISTED
Achaogen Inc
AKAO
$704K 0.44%
+255,000
New +$991K
NKTR icon
40
Nektar Therapeutics
NKTR
$2.55B
$688K 0.43%
+3,333
New +$640K
MDVN
41
DELISTED
MEDIVATION, INC.
MDVN
$667K 0.42%
+14,500
New +$526K
EVOK
42
DELISTED
Evoke Pharma
EVOK
$662K 0.41%
903
– –
PRTA icon
43
Prothena Corp
PRTA
$467M
$576K 0.36%
+14,000
New +$548K
NDRM
44
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$544K 0.34%
+38,500
New +$520K
ALPN
45
DELISTED
Alpine Immune Sciences Inc
ALPN
$417K 0.26%
+25,000
New +$501K
ACRS icon
46
Aclaris Therapeutics
ACRS
$907M
$341K 0.21%
+18,000
New +$344K
BLRX
47
BioLineRX
BLRX
$12.1M
$255K 0.16%
417
– –
CHMA
48
DELISTED
Chiasma, Inc. Common Stock
CHMA
$183K 0.11%
+20,000
New +$216K
AVDL
49
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-250,000
Closed -$3.05M
AXDX
50
DELISTED
Accelerate Diagnostics
AXDX
– –
-7,500
Closed -$1.61M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2016 Portfolio in Review

As of Q1 2016, Opaleye Management held 67 positions worth $160M, down 33% from $239M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management withdrew a net $21.6M in Q1 2016, closing 14 positions and reducing 12 holdings. Its most notable exit was RELYPSA INC COM, an estimated $6.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 88% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Agios Pharmaceuticals worth $4.26M.

  • Opaleye Management's largest Q1 2016 buy was Agios Pharmaceuticals: 105,000 shares worth $4.26M.
  • Opaleye Management added most to Tvardi Therapeutics in Q1 2016, an estimated $3.55M increase.
  • Opaleye Management's biggest Q1 2016 reduction was Supernus Pharmaceuticals, cutting an estimated $3.85M.
  • Opaleye Management fully exited RELYPSA INC COM in Q1 2016, selling an estimated $6.24M.
  • Opaleye Management's ten largest holdings make up 43% of its $160M portfolio in Q1 2016.
  • Opaleye Management opened 14 new positions and closed 14 in Q1 2016.
  • Opaleye Management's portfolio value fell 33% quarter-over-quarter to $160M.

Based on Opaleye Management's 13F filing for Q1 2016, filed 16 May 2016.